1. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
- Author
-
Marta Crespo, Eva Catalá, Isabel Ruiz-Camps, Maria Laura Fox, Guillermo Villacampa, Mónica Martínez-Gallo, Gemma Pujadas, Pau Abrisqueta, Candela Fernández-Naval, Soraya Peralta-Garzón, David Valcárcel, Tomás Pumarola, Moraima Jiménez, Magda Campins, Daniel Medina-Gil, Pere Barba, Alba Cabirta, Cristina Hernández, M. Hernández, Alberto Orfao, Francesc Bosch, Ana Marín-Niebla, Guillermo Ortí, Mercedes Valentín, Marcos González, Juliana Esperalba, Elisa Roldán, Mercedes Gironella, Carlota Pagès Geli, Generalitat de Catalunya, Institut Català de la Salut, [Jiménez M, Roldán E, Gironella M, Fox L, Orti G, Barba P, Valcárcel D, Bosch F, Abrisqueta P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fernández-Naval C, Pumarola T, Esperalba J] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Villacampa G] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martinez-Gallo M, Hernández M] Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Crespo M] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cabirta A, Catalá E, Valentín M, Marín-Niebla A] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Orfao A] Department of Medicine and Cytometry General ServiceNucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. [González M] Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC–CB16/12/00233 and Center for Cancer Research–IBMCC (USAL-CSIC), Salamanca, Spain. [Campins M] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
COVID-19 Vaccines ,Immunobiology and Immunotherapy ,Clinical Trials and Observations ,T cell ,Antibodies, Viral ,Hypogammaglobulinemia ,Immunogenicity, Vaccine ,medicine ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Humans ,RNA, Messenger ,Immune System Phenomena::Antibody Formation::Immunogenicity, Vaccine [PHENOMENA AND PROCESSES] ,neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES] ,BNT162 Vaccine ,Aged ,Response rate (survey) ,Messenger RNA ,business.industry ,SARS-CoV-2 ,Immunogenicity ,Antibody titer ,COVID-19 ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,Regular Article ,Hematology ,Aplasia ,Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES] ,medicine.disease ,Antibodies, Neutralizing ,medicine.anatomical_structure ,Hematologic Neoplasms ,Immunology ,Humoral immunity ,Sang - Malalties ,fenómenos del sistema inmunitario::formación de anticuerpos::inmunogenicidad vacunal [FENÓMENOS Y PROCESOS] ,business ,Immunoglobulines ,COVID-19 (Malaltia) - Vacunació ,2019-nCoV Vaccine mRNA-1273 - Abstract
Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate both the humoral and cellular immunogenicity 1 month after the second dose of the mRNA-1273 vaccine. Antibody titers were measured by using the Elecsys and LIAISON anti–SARS-CoV-2 S assays, and T-cell response was assessed by using interferon-γ release immunoassay technology. Overall, 76.3% (184 of 241) of patients developed humoral immunity, and the cellular response rate was 79% (184 of 233). Hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy during the previous 6 months were associated with an inferior humoral response. Conversely, age >65 years, active disease, lymphopenia, and immunosuppressive treatment of graft-versus-host disease (GVHD) were associated with an impaired cellular response. A significant dissociation between the humoral and cellular responses was observed in patients treated with anti-CD20 therapy (the humoral response was 17.5%, whereas the cellular response was 71.1%). In these patients, B-cell aplasia was confirmed while T-cell counts were preserved. In contrast, humoral response was observed in 77.3% of patients undergoing immunosuppressive treatment of GVHD, whereas only 52.4% had a cellular response. The cellular and humoral responses to the SARS-CoV-2 mRNA-1273 vaccine in patients with hematologic malignancies are highly influenced by the presence of treatments such as anti-CD20 therapy and immunosuppressive agents. This observation has implications for the further management of these patients., The authors also thank the Cellex Foundation for providing research facilities and equipment and the CERCA Programme/Generalitat de Catalunya for institutional support.
- Published
- 2021